Efficacy and Safety of Influenza Vaccination during the First Six Months Post-Transplantation
Enfermedades Infecciosas, Microbiología y Medicina Preventiva, IBIS, Hospital Virgen del Rocío, Sevilla, Spain
Enfermedades Infecciosas y Servicio de Cardiología, IMIBIC, Hospital Universitario Reina Sofia, Cordoba, Spain
Enfermedades Infecciosas, Hospital Vall d´Hebron, Barcelona, Spain
Servicio de Nefrología, Hospitales Virgen del Rocío, Sevilla, Spain
Trasplante Hepático y Cirugía Hepatobiliopancrática, Hospitales Virgen del Rocío, Sevilla, Spain
Servicio de Cardiología, Hospitales Virgen del Rocío, Sevilla, Spain
Meeting: 2013 American Transplant Congress
Abstract number: A588
Our goal was to study the efficacy and safety of influenza vaccination during the first six months post-transplantation.
A prospective cohort study of consecutive cases of influenza vaccinated SOTR was carried out during three influenza seasons: 2009/2010, 2010/2011 and 2011/2012. Antibody responses to influenza A(H1N1)pdm09 were measured at baseline and at 5 weeks after vaccination (adjuvanted influenza A(H1N1)pdm, inactivated trivalent influenza vaccine (TIV) using a microneutralization assay. Patients were followed for one year for clinical outcomes.
A total of 532 SOTR (179 liver, 188 kidney, 102 heart, 57 lung, 6 combined) were included. Of them, 68 (17 liver, 42 kidney, 3 heart, 5 lung, 1 combined) received the vaccine between day 30 and 180 after transplantation: 24 (6.9%) of 346 in 2009/2010, 14 (14.6%) of 96 in 2010/2011 and 30 (33.3%) of 90 in 2011/2012. Patient baseline characteristics were similar except for prevaccination antibody titers, which were significantly higher in patients immunized within 6 months posttransplant (41.2% vs. 23.3%, p=0.002). Titers were: GMTpre (IC95%) 14.6 (range: 9.9-21.5) vs. 9.7 (8.6-10.9; p=0.018), respectively.
The overall rates of seroconversion for patients receiving the vaccine before and after 6 months from transplantation were 64.2% and 69.1% (p=0.25), respectively, and rates of seroprotection were 79.1% and 80.4% (p= 0.46), respectively. The GMTpost (IC95%) was 144.3 (94.2-220.8) vs. 119.9 (102.8-139.9; p=0.405) for patients receiving the vaccine before and after 6 months from transplantation, respectively. Transplanted organ and vaccine type did not affect seroprotection and seroconversion rates. No rejection episodes or adverse effects related to influenza vaccination were detected.
Our results suggest that influenza vaccination of SOTR is safe and efficacious one month after transplant, and therefore could be recommended.
To cite this abstract in AMA style:
Cordero E, Bulnes-Ramos A, Aydillo T, Leon-Jimenez B, Torre-Cisneros J, Lara R, Gavalda J, Gentil M, Gomez M, Lage E, Perez-Romero P. Efficacy and Safety of Influenza Vaccination during the First Six Months Post-Transplantation [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/efficacy-and-safety-of-influenza-vaccination-during-the-first-six-months-post-transplantation/. Accessed May 17, 2025.« Back to 2013 American Transplant Congress